Plain-English translation of NCT07022704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our COPD research guide →This trial is testing whether , a medication that stimulates breathing, helps patients with moderate to severe COPD (chronic obstructive pulmonary disease) who are on mechanical ventilators. Researchers want to see if the medication improves how well the diaphragm — your main breathing muscle — works during a spontaneous breathing trial, when doctors test whether you're ready to breathe on your own.
When patients with severe COPD are on ventilators, their breathing muscles can become weak. This medication might help strengthen breathing effort at a critical moment — when doctors are deciding if you're strong enough to come off the ventilator. Understanding how this treatment affects your breathing muscle could help doctors better prepare patients for this important transition.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive intravenously (through an IV) while undergoing your spontaneous breathing trial. A respiratory ultrasound specialist will use ultrasound imaging to measure how well your diaphragm is moving and working. The study involves 35 patients total and focuses on observing how the medication affects your breathing muscle during this critical weaning process.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
Egypt
Enrollment target
~35 participants
Started
June 2025
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years – 65 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mina Helmy, MD
Cairo University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.